Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin provides a broad mixture of IgG antibodies that bind to pathogens, neutralize toxins, and enhance phagocytosis. It also modulates immune cell activity through Fc‑receptor interactions, suppresses inflammatory cytokines, and helps restore normal immune function in deficient or dysregulated states.

The dose of Octagam is individualized by the prescribing clinician based on the patient’s weight, the specific indication, and clinical response. Typical regimens involve weight‑based dosing administered intravenously over several hours, but exact amounts are determined by the treating physician.

Data on Octagam use during pregnancy and lactation are limited. It may be used when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully and discuss possible risks with the patient.

To order Octagam, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Octagam is comparable to other licensed IVIG preparations such as Gamunex and Privigen in terms of IgG content and clinical indications. Differences may lie in formulation stabilizers, infusion rates, and specific manufacturing processes, which can affect tolerability and handling preferences for individual patients and clinicians.

Octagam must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original container, protected from light, and must never be frozen or shaken. Prior to infusion, the solution may be allowed to reach room temperature if recommended by the manufacturer’s instructions.

Octagam is given as an intravenous infusion. The infusion rate is started slowly and may be increased as tolerated, typically over 2–5 hours depending on the dose and patient’s condition. Administration should be performed by trained healthcare professionals in a setting equipped to manage infusion reactions.

Serious adverse events include anaphylaxis, aseptic meningitis, hemolytic anemia, severe thrombocytopenia, thromboembolic complications, and acute renal failure. Patients should be monitored closely during and after infusion for signs of these reactions, and immediate medical attention is required if they occur.

Octagam is contraindicated in individuals with a known hypersensitivity to human immunoglobulin preparations or any excipients in the product. Patients with selective IgA deficiency who have anti‑IgA antibodies are also at increased risk of severe reactions and should avoid its use unless under strict medical supervision.